Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.38 |
| ▸ | ITGAL | P20701 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063021 | 1.00 | EIF2AK2 (0.43) | EIF2AK2CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL124633 | 0.83 | ITGB2 (0.47) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2ITGB3 | |
| SCHEMBL16265455 | 0.83 | ITGB2 (0.47) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2ITGB3 | |
| SCHEMBL122609 | 0.79 | CSNK2A2 (0.50) | EIF2AK2CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL27815713 | 0.78 | TTR (0.42) | ALDH1A1SMN1; SMN2AKR1C3L3MBTL1HCAR2 | |
| SCHEMBL7890271 | 0.76 | MIF (0.44) | EIF2AK2CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL12984070 | 0.76 | MIF (0.44) | EIF2AK2CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL16634243 | 0.76 | BACE1 (0.47) | EIF2AK2CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL16634244 | 0.76 | BACE1 (0.47) | EIF2AK2CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL909922 | 0.75 | POLB (0.59) | ALDH1A1SMN1; SMN2ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889722-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2184279-B1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | SHIONOGI & CO (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8530668-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | SHIONOGI & CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2010-10-21 | — | — | US | disclosed |
| EP-2184279-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | MPL, TEK, THPO | EIF2AK2 4336/4885CSNK2A2 1776/4885CSNK2B 1551/4885 |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | MPL, TEK, THPO | EIF2AK2 4333/4885CSNK2A2 1784/4885CSNK2B 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.